European archives of psychiatry and clinical neuroscience · 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fava Maurizio, Stahl Stephen M, De Martin Sara, Mattarei Andrea, Bettini Ezio, Comai Stefano, Alimonti Andrea, Bifari Francesco, Pani Luca, Folli Franco, Guidetti Clotilde, Furlan Alberto, Sgrignani Jacopo, Locatelli Patrizia, Cavalli Andrea, O'Gorman Cedric, Traversa Sergio, Inturrisi Charles E, Pappagallo Marco, Manfredi Paolo L
Аннотация
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer's dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.